You know 100% I’m student of Professor Van’s Market and Economics Program and also Political Science Thank You
Bad idea. I just write from the hip when I feel like writing. I do try hard at analyzing fundamentals, but even that... pure amateur.
No matter the degree of pain HF redemption's etc have (and perhaps will) place on tech... and of course the "multiple contraction" which will soon become the buzzword regarding many of these stocks, make no mistake, WS money will ALWAYS pay a premium for quality. Get past the near term noise, have a multi-year outlook... dump the trash... and there's only one tech stock you need in your portfolio.... PANW. They report on the 19th. If they don't revise forward guidance by a jaw-dropping level, I'll quit. PANW--->$305 And it may go lower, but it will be above $470 by this time 2026. The other two stocks if you need two more tech plays... as worn out as it is... TSLA and NVDA. But PANW barring a CRWD-like event, is the big dog. TSLA $207 NVDA $107
SWBI is a (beta) buy here. It will beat the mkt. Their best product lineup in years. Cannot keep their titanium cylinder N-frames and 380s in stock. Carry comps are selling very well.
Ok I'll look. I just logged on to give out what I think will be a good earnings play as well as a long term hold. OSUR ---> Orasure Technologies. $4.31 It's a medical device and testing company. https://orasure.com/ I've followed the story and they are on the upswing. It's very well run. They are going to beat and raise, I'm pretty sure. Here's the crown jewel : We ended the quarter with zero debt and total cash, cash equivalents and short-term investments of $290 million, which is $65 million increase from the prior quarter. The increase in our cash balance during the fourth quarter was primarily driven by $41 million of operating cash flow. There is only 74M shares outstanding. That is $3.91/share. You're buying this company for $0.40/ share. Here's something I learned lol... the incidence of Syphilis is exploding, both in the US and worldwide (so you young bucks best be careful). https://www.nytimes.com/2024/07/25/opinion/syphilis-disease-rates-rising.html These guys just inked a deal with a NJ company, leveraging OSUR's worldwide distribution network to distribute this NJ company's rapid Syphilis test kits. They say it will bump revenue by 2% in 2024. Talk about good timing. They're also in bed with the U.S. Government for Covid testing, and they just got a bonus check for completing the expansion of a production facility early. The way I read it, the facility can be utilized to make testing kits for whatever may come down the road. They also do E-Bola stuff. And rapid drug testing kits. Folks interested can read about their products in the above link. I don't need to cover all that. I like the story and I like the management's cost-cutting initiatives to improve GAAP margins. I think they sand-bagged guidance, and I think they are going to beat/beat/raise. Not by much, because they're very prudent... but the story's there. It's my top pick for the week. It's a good one considering this market atm. This company is not affected by the Fed, Iran/Israel, etc. As always... do your own dd.
ZoomInfo (ZI) reports after the bell. It has been beaten down pretty badly. $10.41 I think if it gets hammered on earnings and drops into the $9's, it might be worth a look. There's a lot of bearish sentiment floating around out there right now. All based on those job numbers lol!? Pfff. I'm not buying it. Our economy is firing on all cylinders. This sell-off was just the big algos raking the table. We're gonna bounce. BTFD.
I like Chubb for earnings too btw. CB----> $271.32 Good fundamentals, 10X cash-flow, 19% net margins, great chart, and close enough to the bottom of a rising channel to break out to the upside nicely. It's up 30% yoy, and 20% ytd, so it may fall a little towards the 200 day, but I suspect any pullback on earnings will be quickly bought. These type of companies lol, they don't know how to lose money. They just adjust their rates to keep their multi-year chart moving up and to the right. And this one's a mammoth.